A research team from the University of Rochester, Harvard Medical School, and Boston Children’s Hospital reports that an inclusion-complex nano‑micelle formulation of cannabidiol, called CBD‑IN, rapidly reduced neuropathic pain in mice and did so without detectable balance, movement, or memory problems. The study, published online ahead of print in Cell Chemical Biology on November 7, 2025, suggests the effect did not depend on the classic CB1 or CB2 cannabinoid receptors.
Scientists have struggled to map how cannabidiol (CBD) influences the nervous system, in part because CBD’s poor water solubility limits how much reaches the brain. According to a University of Rochester Medical Center (URMC) summary, researchers addressed this by enclosing CBD in a water‑soluble inclusion‑complex nano‑micelle formulation—CBD‑IN—that raised brain levels of the compound in mice.
In mouse tests, a single dose of CBD‑IN alleviated neuropathic pain within about 30 minutes and maintained efficacy with repeated dosing, without signs of tolerance, URMC reports. Mice did not show impairments in sensorimotor or cognitive performance—findings consistent with the peer‑reviewed paper’s description that CBD‑IN suppressed pain “without impairing normal sensorimotor or cognitive functions.” The team’s activity‑mapping and calcium‑imaging data indicated that CBD‑IN dampened abnormal neural activity across pain‑processing circuits while largely sparing healthy neurons.
The Rochester summary also notes that the analgesic effect did not rely on CB1 or CB2—the typical cannabinoid receptors engaged by THC—pointing instead toward broader modulation of electrical and calcium signaling in neurons. While this receptor‑independent mechanism is intriguing, the results are preclinical and limited to mice; human studies will be needed to determine safety, dosing, and efficacy in patients.
The project was led by Kuan Hong Wang, PhD (University of Rochester/Del Monte Institute for Neuroscience), with staff scientist and first author Jingyu Feng, PhD. URMC identifies Jessica Page, PhD, and Leeyup Chung, PhD, as co‑first authors and Zhigang He, PhD (Harvard Medical School/Boston Children’s Hospital), as co‑senior author. Funding came from the National Institutes of Health and the Del Monte Institute for Neuroscience.
Regulatory context: The 2018 Agriculture Improvement Act (the “Farm Bill”) removed hemp—defined as cannabis with no more than 0.3% delta‑9 THC—from the Controlled Substances Act, enabling federally lawful production of hemp‑derived cannabinoids when compliant with federal and state programs. However, the U.S. Food and Drug Administration has approved only one CBD medicine—Epidiolex—for treating seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year and older, and the agency advises against using CBD during pregnancy or while breastfeeding.
Publication details: Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano‑formulated cannabidiol. Cell Chemical Biology. Online ahead of print November 7, 2025. DOI: 10.1016/j.chembiol.2025.10.005.
